| Name | Title | Contact Details |
|---|---|---|
Joshua Goldberg |
Senior Director, IT and Security | Profile |
Nicholas Parker |
Chief Technology Officer | Profile |
Morristown Manor is a Morristown, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
C C Young is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Dallas, TX. To find more information about C C Young, please visit www.ccyoung.org
BeneChill is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.
RIO attains its goal of improving the quality of life of disabled persons by providing comprehensive, coordinated programs which increase the ability of disabled individuals to function at home and at school, on the job, and in the community. RIO was established in 1950 to serve the multi-faceted needs of persons with functional disabilities caused by birth defects, medical condition or accidents. Services are provided without regard to age, race, creed, sexual orientation, and gender.